HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut

A trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public trading debuts with more than $850 million combined. Seaport Therapeutics, Hemab Therapeutics and Avalyn Pharma are the ...

By Endpoints News · May 1, 2026 · via Endpoints News
Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut

Image: Endpoints News

This is an aggregated industry headline. Read the full story at Endpoints News →

Tags
moneyformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio
MoneyFiercePharma ↗
BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star hear…
May 5, 2026
With $97M, Latus pursues a different kind of Huntington’s gene therapy
MoneyBioPharma Dive ↗
With $97M, Latus pursues a different kind of Huntington’s gene therapy
The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enab…
May 4, 2026
Seaport’s $255M Upsized IPO Defies the Big Pharma M&A Pull
MoneyBriefing
Seaport’s $255M Upsized IPO Defies the Big Pharma M&A Pull
Seaport Therapeutics opted for a $255M Nasdaq IPO over an acquisition, underscoring renewed investor appetite …
May 3, 2026